ZEAL
Zealand Sp ADR

360
Mkt Cap
$814.08M
Volume
2,157.00
52W High
$32.94
52W Low
$9.93
PE Ratio
-4.51
ZEAL Fundamentals
Price
$17.59
Prev Close
$17.38
Open
$18.03
50D MA
$18.01
Beta
0.75
Avg. Volume
3,890.65
EPS (Annual)
-$1.81
P/B
11.47
Rev/Employee
$197,501.84
Loading...
Loading...
News
all
press releases
OTR Therapeutics and Zealand Pharma enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases
OTR Therapeutics and Zealand Pharma enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases OTR Therapeutics and Zealand Pharma enter...
PR Newswire·17h ago
News Placeholder
More News
News Placeholder
Zealand Pharma shares leap after Wells Fargo’s new Buy coverage
Investing.com -- Wells Fargo has initiated coverage of Zealand Pharma (NASDAQ:ZEAL) with an Overweight rating and a DKK 650 price target, seeing the Danish biotech as poised to become “a key obesity player” thanks to its differentiated pipeline targeting the rapidly expanding weight loss market.
investing.com·5mo ago
News Placeholder
European pharmaceutical shares edge lower after Trump threatens 200% drug tariff
Investing.com - Shares of European drugmakers slipped on Wednesday after U.S. President Donald Trump said that tariffs of up to 200% on pharmaceutical imports could be coming "very soon."
investing.com·5mo ago
News Placeholder
Morgan Stanley upgrades Zealand Pharma to Buy on 'long-term obesity potential'
Investing.com -- Morgan Stanley upgraded its rating on Zealand Pharma (NASDAQ:ZEAL) shares to Overweight from Equal Weight, highlighting a “long-term obesity potential” unlocked by the company’s recent partnership with Roche (SIX:ROG).
investing.com·9mo ago
News Placeholder
Zealand Pharma, Roche have 2 best-in-class obesity assets, CEO tells Investing.com
Investing.com -- Zealand Pharma shares surged more than 41% on Wednesday after announcing a $5.3 billion licensing deal with Roche for its GLP-1 obesity therapy petrelintide. 
investing.com·9mo ago
News Placeholder
NovoNordisk stock falls on Roche-Zealand pact; Jefferies cuts target
Investing.com -- Novo Nordisk (CSE:NOVOb) (NYSE:NVO) shares slumped Wednesday after Roche (SIX:ROG) struck a $5.3 billion deal to acquire rights to an obesity treatment from Denmark’s Zealand Pharma A/S (CSE:ZELA).
investing.com·9mo ago
News Placeholder
Zealand Pharma stock falls loss widens, revenue declines
investing.com·10mo ago

Latest ZEAL News

View

Advertisement|Remove ads.

Advertisement|Remove ads.